Trials / No Longer Available

No Longer AvailableNCT03206931

Expanded Access to Provide Selitrectinib for the Treatment of Cancers With a NTRK Gene Fusion

Expanded Access to Provide Selitrectinib (BAY2731954) for the Treatment of Cancers With a NTRK Gene Fusion.

Status: No Longer Available
Phase: —
Study type: Expanded Access
Enrollment: —

Sponsor: Bayer · Industry
Sex: All
Age: 1 Month
Healthy volunteers: —

Summary

Selitrectinib expanded access is for minor and adult patients with cancer having a change in a particular gene (NTRK1, NTRK2, or NTRK3 gene fusion). The patients are ineligible for an ongoing selitrectinib clinical trial or have other considerations that prevent access to selitrectinib through an existing clinical trial. Expanded access is intended to treat individual patients with different types of cancers with a NTRK gene fusion, including blood cancers, who have previously received tropomyosin receptor kinase (TRK) inhibitor therapy.

Conditions

Solid Tumors Harboring NTRK Fusion

Interventions

Type	Name	Description
DRUG	Selitrectinib (BAY2731954)	Selitrectinib is administered as capsules or liquid formulation.

Timeline

First posted: 2017-07-02
Last updated: 2021-09-16

Source: ClinicalTrials.gov record NCT03206931. Inclusion in this directory is not an endorsement.